Recent Patents on Endocrine, Metabolic & Immune Drug Discovery


Recent Efforts to Develop Imaging Methods and β -Cell-Specific Contrast Agents for Non-Invasive in vivo Assessment of β-Cell Mass

Author(s): Stephan Schneider, John Virostko, Astrid Reimann and Alvin C. Powers

Affiliation: Medical Department 1, Division of Endocrinology and Metabolism, University Hospital Bergmannsheil, Ruhr-University of Bochum, Bürkle de la Camp Platz 1, 44789 Bochum, Germany.

Keywords: Non-invasive imaging, β-cell mass, imaging probes, BLI, MRI, PET


Accurate, non-invasive assessment of the endogenous pancreatic β-cell mass in humans is currently not feasible. The development of a non-invasive assay of β-cell mass would be invaluable in the study of the natural course of diabetes and ongoing attempts to preserve or restore β-cell mass in patients with diabetes. This article reviews imaging methods and radiolabeled ligands which have been proposed or used for non-invasive assessment of the endogenous β- cell mass and discusses patents and future directions for the development of β-cell specific contrast agents.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [157 - 161]
Pages: 5
DOI: 10.2174/187221409789104737